Bioreperia
Latest round
- Series A
Last raised
- Jun 2019
Total raised
- $0.9M
Investors
- 2
About Bioreperia
Founded in 2015 in Linkoping, Sweden, Bioreperia AB focuses on oncology drug discovery, utilizing its unique ZTX® platform. The company has not undergone significant strategic pivots and does not have known subsidiaries. Its founding team includes Anna Fahlgren, while Anna Erkstam serves as the CEO., as the company’s first significant investment target.BioReperia offers oncology solutions through its proprietary ZTX® platform, which encompasses ZTX™ ONCOLEADS and ZTX™ PREDICT. ZTX™ ONCOLEADS is an in-vivo drug discovery tool that accurately mimics the tumor microenvironment for rapid selection of lead candidates, while ZTX™ PREDICT tailors cancer treatment recommendations based on individual patient profiles.80. The company is focused on designing new solutions to improve oncology drug discovery, although specific upcoming product release dates have not been disclosed. Bioreperia also plans to enter new geographic markets, specifically targeting Asia and North America, by 2025.
Who invested in Bioreperia
2 investors across 1 round
See all investors in Bioreperia
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 28, 2019
Amount
$0.9M
Investors
Questions about Bioreperia
Who invested in Bioreperia?
Bioreperia has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bioreperia raised?
Bioreperia has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Bioreperia last raise money?
Bioreperia's most recent round on record is a Series A, in Jun 2019.
What does Bioreperia do?
Founded in 2015 in Linkoping, Sweden, Bioreperia AB focuses on oncology drug discovery, utilizing its unique ZTX® platform.
Where is Bioreperia headquartered?
Bioreperia is headquartered in Linkoping, Sweden.
Which VCs invest in companies like Bioreperia?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Bioreperia's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Bioreperia? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.